Meeting
2012 ASCO Annual Meeting
Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
Authors
Dong-Wan Kim
Seoul National University Hospital, Seoul, South Korea
Dong-Wan Kim , Myung-Ju Ahn , Yuankai Shi , Tommaso Martino De Pas , Pan-Chyr Yang , Gregory J. Riely , Lucio Crinò , Tracey L. Evans , Xiaoqing Liu , Ji-Youn Han , Ravi Salgia , Denis Moro-Sibilot , Sai-Hong Ignatius Ou , Scott N. Gettinger , Yi Long Wu , Silvana Lanzalone , Anna Polli , Shrividya Iyer , Alice Tsang Shaw
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00932451
Citation
J Clin Oncol 30, 2012 (suppl; abstr 7533)
DOI
10.1200/jco.2012.30.15_suppl.7533
Abstract #
7533
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC).
First Author: Vera Hirsh
Poster
2022 ASCO Annual Meeting
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx)-naïve patients with advanced non–small cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, multicenter, phase 2 study.
First Author: Tony S. K. Mok
Poster
2019 ASCO Annual Meeting
Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.
First Author: Edward S. Kim
Poster
2017 ASCO Annual Meeting
Patient-reported outcomes and quality of life in ALTA: The randomized phase 2 study of brigatinib (BRG) in advanced ALK+ non–small cell lung cancer (NSCLC).
First Author: Corey J. Langer